Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
Latest Information Update: 03 Oct 2021
Price :
$35 *
At a glance
- Drugs Endostatin (Primary) ; Cisplatin; Docetaxel
- Indications Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Sep 2012 New source identified and integrated (ClinicalTrials.gov record: NCT01689558)
- 24 Sep 2012 Planned End Date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
- 15 Aug 2012 New trial record